MicroPort<sup>®</sup> Attends the Ninth Oriental Cardiology Meeting

From September 10 to September 13, the 17th National Cardiovascular Conference of Chinese Medicine Association and the ninth Oriental Cardiology Conference ("CSC&OCC2015") was held in Shanghai. Nearly 10000 experts and scholars attended. Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") held a special satellite meeting in the conference to present the independently designed Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®"). MicroPort® shared to the attendees the latest research results of applying Firehawk® in Clinical trial, evaluated Firehawk® in Health Economics, and comprehensively displayed the uniqueness and superiority of Firehawk®.
 
This special satellite meeting was organized by MicroPort® and held on September 12. Professor Weiyi Fang from Shanghai Chest Hospital, Professor Zuyi Yuan from the First Affiliated Hospital of Xi'an Jiaotong University, Professor Zhanquan Li from the People's Hospital of Liaoning Province, Professor Lianglong Chen from Fujian Medical University Union Hospital and Professor Ruqiong Nie from Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University were invited as chairmen of the satellite meeting. Professor Bo Xu, the Director of Fuwai Hospital presented a report titled "the new progress of clinical trials applying Firehawk®", shows the excellent clinical trial results of Firehawk®, and spoke highly of its safety and efficacy.
 
Professor Xiaohua Ying from the School of Public Health, Fudan University gave the following comments:" Firehawk® has better therapeutic effect in treating patients with single coronary artery lesion in single vessel, compared to imported stents of the same price." Professor Yong Xia from the Affiliated Hospital of Xuzhou Medical College shared a real case of Firehawk® with people, showing the excellent performance of Firehawk® in clinical practice to the participants earnestly.
 
MicroPort® held "Firehawk-Follow-2015 clinical research program and project opening meeting" on September 11. Wei Yi Fang, professor from Shanghai Chest Hospital, as the main researcher, presented the "Firehawk-Follow-2015" project to the attendees. The purpose of the project is to verify the safety and efficacy of Firehawk® in real cases. The participating experts presented and discussed the clinical research programs of Firehawk®.
 
During the meeting, Professor Guosheng Fu from Sir Run Run Shaw Hospital School of Medical, Zhejiang University had an interview with "Clinic" magazine. He expressed that the unique design of the groove of Firehawk® can reduce the risk of restenosis. Professor Jian An Wang from the Second Affiliated Hospital of Zhejiang University School of Medical said that the Firehawk® can reduce the time of DAPT, and he believed that if there had been more data support in real cases, Firehawk® would have been the leap progress in the field as a domestic stent. Professor Jincheng Guo from Beijing Luhe Hospital, Capital Medical University pointed out that in accordance with the definition of the ESC guidelines for a new generation of eluting stents, Firehawk® will become the most outstanding stents product after obtaining more clinical data support.